PCVX vs SNY
Vaxcyte, Inc. vs Sanofi — AI-powered side-by-side comparison
PCVX
Vaxcyte, Inc.
66
Insufficient Data
VS
SNY
Sanofi
62
Insufficient Data
| Metric | PCVX | SNY |
|---|
| AI Score |
66
|
62
|
| Price |
$59.22
|
$43.56
|
| P/E Ratio |
-7.75×
|
23.06×
|
| ROE |
-28.5%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
72.8%
|
| Debt / Equity |
0.04×
|
0.34×
|
| Dividend Yield |
0.0%
|
5.5%
|
| RSI (14) |
65.6
|
53.1
|
| Beta |
1.21
|
0.278
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for PCVX versus SNY.
PCVX leads by 4 points.
PCVX scores 66/100 (Insufficient Data) versus SNY at 62/100 (Insufficient Data).
PCVX Committee View
67% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
SNY Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Trend and market structure agree -- coherent bearish picture — Technical